Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19


Diffuse and focal corticospinal tract disease and its impact on patient disability in multiple sclerosis.

Tovar-Moll F, Evangelou IE, Chiu AW, Auh S, Chen C, Ehrmantraut M, Ohayon JM, Richert N, Bagnato F.

J Neuroimaging. 2015 Mar-Apr;25(2):200-206. doi: 10.1111/jon.12171. Epub 2014 Oct 16.


Cognitive impairment and its relation to imaging measures in multiple sclerosis: a study using a computerized battery.

Pellicano C, Kane RL, Gallo A, Xiaobai L, Stern SK, Ikonomidou VN, Evangelou IE, Ohayon JM, Ehrmantraut M, Cantor FK, Bagnato F.

J Neuroimaging. 2013 Jul;23(3):445-52. doi: 10.1111/j.1552-6569.2011.00687.x. Epub 2012 Dec 10.


T1 cortical hypointensities and their association with cognitive disability in multiple sclerosis.

Bagnato F, Salman Z, Kane R, Auh S, Cantor FK, Ehrmantraut M, Gallo A, Ikonomidou VN, Ohayon J, Pellicano C, Stern SK, McFarland HF.

Mult Scler. 2010 Oct;16(10):1203-12. doi: 10.1177/1352458510377223. Epub 2010 Aug 10.


Quality and quantity of diffuse and focal white matter disease and cognitive disability of patients with multiple sclerosis.

Bomboi G, Ikonomidou VN, Pellegrini S, Stern SK, Gallo A, Auh S, Evangelou IE, Agarwal J, Pellicano C, Ohayon JM, Cantor FK, Ehrmantraut M, McFarland HF, Kane RL, Bagnato F.

J Neuroimaging. 2011 Apr;21(2):e57-63. doi: 10.1111/j.1552-6569.2010.00488.x.


Relationship of cortical atrophy to fatigue in patients with multiple sclerosis.

Pellicano C, Gallo A, Li X, Ikonomidou VN, Evangelou IE, Ohayon JM, Stern SK, Ehrmantraut M, Cantor F, McFarland HF, Bagnato F.

Arch Neurol. 2010 Apr;67(4):447-53. doi: 10.1001/archneurol.2010.48.


Thalamic involvement and its impact on clinical disability in patients with multiple sclerosis: a diffusion tensor imaging study at 3T.

Tovar-Moll F, Evangelou IE, Chiu AW, Richert ND, Ostuni JL, Ohayon JM, Auh S, Ehrmantraut M, Talagala SL, McFarland HF, Bagnato F.

AJNR Am J Neuroradiol. 2009 Aug;30(7):1380-6. doi: 10.3174/ajnr.A1564. Epub 2009 Apr 15.


Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study.

Chiu AW, Richert N, Ehrmantraut M, Ohayon J, Gupta S, Bomboi G, Gaindh D, Cantor FK, Frank JA, McFarland HF, Bagnato F.

Arch Neurol. 2009 Jan;66(1):39-43. doi: 10.1001/archneur.66.1.noc80047. Epub 2008 Nov 10.


Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome.

Kim RD, Greenberg DE, Ehrmantraut ME, Guide SV, Ding L, Shea Y, Brown MR, Chernick M, Steagall WK, Glasgow CG, Lin J, Jolley C, Sorbara L, Raffeld M, Hill S, Avila N, Sachdev V, Barnhart LA, Anderson VL, Claypool R, Hilligoss DM, Garofalo M, Fitzgerald A, Anaya-O'Brien S, Darnell D, DeCastro R, Menning HM, Ricklefs SM, Porcella SF, Olivier KN, Moss J, Holland SM.

Am J Respir Crit Care Med. 2008 Nov 15;178(10):1066-74. doi: 10.1164/rccm.200805-686OC. Epub 2008 Aug 14.


Teleneurology in patients with multiple sclerosis: EDSS ratings derived remotely and from hands-on examination.

Kane RL, Bever CT, Ehrmantraut M, Forte A, Culpepper WJ, Wallin MT.

J Telemed Telecare. 2008;14(4):190-4. doi: 10.1258/jtt.2008.070904.


A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging.

Chiu AW, Ehrmantraut M, Richert ND, Ikonomidou VN, Pellegrini S, McFarland HF, Frank JA, Bagnato F.

Clin Exp Immunol. 2007 Oct;150(1):61-7. Epub 2007 Jul 30.


Beta-2-adrenergic receptor polymorphisms in cystic fibrosis.

Steagall WK, Barrow BJ, Glasgow CG, Mendoza JW, Ehrmantraut M, Lin JP, Insel PA, Moss J.

Pharmacogenet Genomics. 2007 Jun;17(6):425-30.


Veterans Health Administration multiple sclerosis surveillance registry: The problem of case-finding from administrative databases.

Culpepper WJ 2nd, Ehrmantraut M, Wallin MT, Flannery K, Bradham DD.

J Rehabil Res Dev. 2006 Jan-Feb;43(1):17-24.


Clinical and imaging metrics for monitoring disease progression in patients with multiple sclerosis.

Bagnato F, Ohayon JM, Ehrmantraut M, Chiu AW, Riva M, Ikonomidou VN.

Expert Rev Neurother. 2006 Apr;6(4):599-612. Review.


Association of common haplotypes of surfactant protein A1 and A2 (SFTPA1 and SFTPA2) genes with severity of lung disease in cystic fibrosis.

Choi EH, Ehrmantraut M, Foster CB, Moss J, Chanock SJ.

Pediatr Pulmonol. 2006 Mar;41(3):255-62.


Auto-ADP-ribosylation of Pseudomonas aeruginosa ExoS.

Riese MJ, Goehring UM, Ehrmantraut ME, Moss J, Barbieri JT, Aktories K, Schmidt G.

J Biol Chem. 2002 Apr 5;277(14):12082-8. Epub 2002 Jan 30.


Children with cystic fibrosis produce an immune response against exoenzyme S, a type III cytotoxin of Pseudomonas aeruginosa.

Banwart B, Splaingard ML, Farrell PM, Rock MJ, Havens PL, Moss J, Ehrmantraut ME, Frank DW, Barbieri JT.

J Infect Dis. 2002 Jan 15;185(2):269-70. No abstract available.


Sera from adult patients with cystic fibrosis contain antibodies to Pseudomonas aeruginosa type III apparatus.

Moss J, Ehrmantraut ME, Banwart BD, Frank DW, Barbieri JT.

Infect Immun. 2001 Feb;69(2):1185-8.


Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in alpha1-antitrypsin deficiency.

Novoradovsky A, Brantly ML, Waclawiw MA, Chaudhary PP, Ihara H, Qi L, Eissa NT, Barnes PM, Gabriele KM, Ehrmantraut ME, Rogliani P, Moss J.

Am J Respir Cell Mol Biol. 1999 Mar;20(3):441-7.


Influence of 6-hydroxydopamine on ethanol narcosis in mice.

Sierralta F, Acevedo X, Ehrmantraut M, Muñoz C.

Acta Physiol Pharmacol Latinoam. 1989;39(3):307-14.


Supplemental Content

Loading ...
Support Center